{"id":"https://openalex.org/W2802491527","doi":"https://doi.org/10.1080/14737167.2018.1467270","title":"Cost effectiveness vs. affordability in the age of immuno-oncology cancer drugs","display_name":"Cost effectiveness vs. affordability in the age of immuno-oncology cancer drugs","publication_year":2018,"publication_date":"2018-04-23","ids":{"openalex":"https://openalex.org/W2802491527","doi":"https://doi.org/10.1080/14737167.2018.1467270","mag":"2802491527","pmid":"https://pubmed.ncbi.nlm.nih.gov/29681201"},"language":"en","primary_location":{"id":"doi:10.1080/14737167.2018.1467270","doi":"https://doi.org/10.1080/14737167.2018.1467270","is_oa":false,"landing_page_url":"https://doi.org/10.1080/14737167.2018.1467270","pdf_url":null,"source":{"id":"https://openalex.org/S98544388","display_name":"Expert Review of Pharmacoeconomics & Outcomes Research","issn_l":"1473-7167","issn":["1473-7167","1744-8379"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["abdc-c","anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Review of Pharmacoeconomics & Outcomes Research","raw_type":"journal-article"},"volume":null,"type":"review","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5078386925","display_name":"George Dranitsaris","orcid":"https://orcid.org/0000-0002-1637-3122","observed_orcids":["https://orcid.org/0000-0002-1637-3122"]},"institutions":[{"id":"https://openalex.org/I4210128961","display_name":"Augmentium Pharma Consulting (Canada)","ror":"https://ror.org/032vq8n85","country_code":"CA","type":"company","lineage":["https://openalex.org/I4210128961"]}],"countries":["CA"],"is_corresponding":true,"raw_author_name":"George Dranitsaris","raw_affiliation_strings":["Augmentium Pharma Consulting Inc., Toronto, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Augmentium Pharma Consulting Inc., Toronto, Canada","institution_ids":["https://openalex.org/I4210128961"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110638341","display_name":"Xiaofu Zhu","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405258411","display_name":"Cross Cancer Institute","ror":"https://ror.org/00m3k3802","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I4405258411"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Xiaofu Zhu","raw_affiliation_strings":["Cross Cancer Institute, Edmonton, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cross Cancer Institute, Edmonton, Canada","institution_ids":["https://openalex.org/I4405258411"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017690706","display_name":"Georges Adunlin","orcid":"https://orcid.org/0000-0002-6146-2802","observed_orcids":["https://orcid.org/0000-0002-6146-2802"]},"institutions":[{"id":"https://openalex.org/I83321563","display_name":"Samford University","ror":"https://ror.org/0040cz635","country_code":"US","type":"education","lineage":["https://openalex.org/I83321563"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Georges Adunlin","raw_affiliation_strings":["School of Pharmacy, Samford University, Birmingham, AL, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"School of Pharmacy, Samford University, Birmingham, AL, USA","institution_ids":["https://openalex.org/I83321563"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5108300199","display_name":"Mark David Vincent","orcid":"https://orcid.org/0000-0001-9551-2831","observed_orcids":["https://orcid.org/0000-0001-9551-2831"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mark D Vincent","raw_affiliation_strings":["London Regional Cancer Program, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"London Regional Cancer Program, Canada","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5078386925"],"corresponding_institution_ids":["https://openalex.org/I4210128961"],"apc_list":null,"apc_paid":null,"fwci":1.5717,"has_fulltext":false,"cited_by_count":54,"citation_normalized_percentile":{"value":0.82982792,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"18","issue":"4","first_page":"351","last_page":"357"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12708","display_name":"Economic and Financial Impacts of Cancer","score":0.5615000128746033,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},"topics":[{"id":"https://openalex.org/T12708","display_name":"Economic and Financial Impacts of Cancer","score":0.5615000128746033,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.2964000105857849,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.10360000282526016,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/cancer-immunotherapy","display_name":"cancer immunotherapy","score":0.9589999914169312},{"id":"https://openalex.org/keywords/cost-effectiveness","display_name":"cost-effectiveness","score":0.8460000157356262},{"id":"https://openalex.org/keywords/drug-affordability","display_name":"drug affordability","score":0.9200000166893005},{"id":"https://openalex.org/keywords/treatment-costs","display_name":"treatment costs","score":0.6650000214576721},{"id":"https://openalex.org/keywords/patient-access","display_name":"patient access","score":0.7080000042915344},{"id":"https://openalex.org/keywords/health-system-sustainability","display_name":"health system sustainability","score":0.5339999794960022},{"id":"https://openalex.org/keywords/melanoma","display_name":"melanoma","score":0.7960000038146973},{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.9990000128746033},{"id":"https://openalex.org/keywords/hodgkin-lymphoma","display_name":"Hodgkin's disease","score":0.7049999833106995},{"id":"https://openalex.org/keywords/tumor-associated-antigens","display_name":"tumor-associated antigens","score":0.6159999966621399}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8019105195999146},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.5663605332374573},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.519254207611084},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.5068429112434387},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.502385139465332},{"id":"https://openalex.org/C2780352672","wikidata":"https://www.wikidata.org/wiki/Q504775","display_name":"Bladder cancer","level":3,"score":0.49513640999794006},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.48940983414649963},{"id":"https://openalex.org/C2779951463","wikidata":"https://www.wikidata.org/wiki/Q7268788","display_name":"Quality of life (healthcare)","level":2,"score":0.4842057228088379},{"id":"https://openalex.org/C2781068499","wikidata":"https://www.wikidata.org/wiki/Q3242950","display_name":"Kidney cancer","level":3,"score":0.4708874821662903},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.4701782763004303},{"id":"https://openalex.org/C3019080777","wikidata":"https://www.wikidata.org/wiki/Q1754768","display_name":"Cost effectiveness","level":2,"score":0.44431376457214355},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4154907166957855},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.41169121861457825},{"id":"https://openalex.org/C112930515","wikidata":"https://www.wikidata.org/wiki/Q4389547","display_name":"Risk analysis (engineering)","level":1,"score":0.1149781346321106},{"id":"https://openalex.org/C159110408","wikidata":"https://www.wikidata.org/wiki/Q121176","display_name":"Nursing","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000074322","descriptor_name":"Antineoplastic Agents, Immunological","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D000074322","descriptor_name":"Antineoplastic Agents, Immunological","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D003362","descriptor_name":"Cost-Benefit Analysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007167","descriptor_name":"Immunotherapy","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D007167","descriptor_name":"Immunotherapy","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":true},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D016527","descriptor_name":"Drug Costs","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1080/14737167.2018.1467270","doi":"https://doi.org/10.1080/14737167.2018.1467270","is_oa":false,"landing_page_url":"https://doi.org/10.1080/14737167.2018.1467270","pdf_url":null,"source":{"id":"https://openalex.org/S98544388","display_name":"Expert Review of Pharmacoeconomics & Outcomes Research","issn_l":"1473-7167","issn":["1473-7167","1744-8379"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["abdc-c","anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Review of Pharmacoeconomics & Outcomes Research","raw_type":"journal-article"},{"id":"pmid:29681201","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/29681201","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert review of pharmacoeconomics & outcomes research","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9391000270843506,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":38,"referenced_works":["https://openalex.org/W1514412248","https://openalex.org/W1595046345","https://openalex.org/W1965870971","https://openalex.org/W1972772656","https://openalex.org/W1997104993","https://openalex.org/W2037139573","https://openalex.org/W2057270791","https://openalex.org/W2079018735","https://openalex.org/W2097995306","https://openalex.org/W2099725888","https://openalex.org/W2104231624","https://openalex.org/W2121314233","https://openalex.org/W2143363270","https://openalex.org/W2145835533","https://openalex.org/W2149322936","https://openalex.org/W2209812019","https://openalex.org/W2344034377","https://openalex.org/W2415125269","https://openalex.org/W2469255185","https://openalex.org/W2502096301","https://openalex.org/W2529904548","https://openalex.org/W2535760099","https://openalex.org/W2542713996","https://openalex.org/W2578581270","https://openalex.org/W2602828273","https://openalex.org/W2621710038","https://openalex.org/W2624805660","https://openalex.org/W2625652544","https://openalex.org/W2711613673","https://openalex.org/W2749428689","https://openalex.org/W2753432434","https://openalex.org/W2765643657","https://openalex.org/W2767047569","https://openalex.org/W2771850922","https://openalex.org/W2792937256","https://openalex.org/W2991189285","https://openalex.org/W4229885848","https://openalex.org/W4232914613"],"related_works":["https://openalex.org/W2766883711","https://openalex.org/W4399700028","https://openalex.org/W4293098482","https://openalex.org/W4233539689","https://openalex.org/W3128990877","https://openalex.org/W4386476688","https://openalex.org/W2252572697","https://openalex.org/W2947018065","https://openalex.org/W2888071581","https://openalex.org/W2980573672"],"abstract_inverted_index":{"INTRODUCTION:":[0],"After":[1],"years":[2],"of":[3,78,136,148,181],"setback,":[4],"cancer":[5,21,40,65],"immunotherapy":[6],"has":[7],"begun":[8],"to":[9,38,53,58,63,161],"yield":[10],"clinical":[11,175],"dividends,":[12],"which":[13,125],"are":[14,48,177,198],"changing":[15],"the":[16,23,35,60,76,110,137,145,151,168],"treatment":[17,123],"landscape":[18],"and":[19,31,46,89,100,116,144,172,189,195],"offering":[20],"patients":[22,115],"potential":[24],"for":[25,114,157],"long-term":[26,196],"survival,":[27],"reduced":[28],"treatment-related":[29],"toxicity":[30],"improved":[32],"quality-of-life.":[33],"Using":[34],"immune":[36,61],"system":[37,62],"treat":[39],"is":[41,122,155,186],"known":[42],"as":[43,87,104,106],"'Immuno-oncology'":[44],"(IO)":[45],"agents":[47,81],"sub-classified":[49],"by":[50],"their":[51],"ability":[52],"enhance":[54],"anti-tumor":[55],"response":[56],"or":[57],"direct":[59],"attack":[64],"cells":[66],"via":[67],"tumor-associated":[68],"antigens.":[69],"Areas":[70],"covered:":[71],"Clinical":[72],"trials":[73],"have":[74],"demonstrated":[75],"effectiveness":[77,183],"several":[79],"IO":[80,170],"in":[82,174],"many":[83],"disease":[84,142],"sites":[85],"such":[86],"early":[88],"advanced":[90,93],"stage":[91],"melanoma,":[92],"non-small":[94],"cell":[95],"lung":[96],"cancer,":[97],"bladder,":[98],"head":[99],"neck,":[101],"gastric,":[102],"kidney":[103],"well":[105],"Hodgkin's":[107],"lymphoma.":[108],"Notwithstanding":[109],"therapeutic":[111],"excitement":[112],"generated":[113],"clinicians":[117],"alike,":[118],"an":[119],"important":[120],"consideration":[121],"cost,":[124],"can":[126],"reach":[127],"more":[128],"than":[129],"$US100,000":[130],"per":[131],"patient":[132,193],"annually.":[133],"The":[134,179],"cost":[135,153,182],"drugs,":[138],"coupled":[139],"with":[140],"high":[141],"prevalence":[143],"ever-expanding":[146],"number":[147],"indications,":[149],"means":[150],"current":[152],"trajectory":[154],"untenable":[156],"most":[158],"healthcare":[159],"systems":[160],"sustain.":[162],"Expert":[163],"commentary:":[164],"In":[165],"this":[166],"paper,":[167],"approved":[169],"drugs":[171],"those":[173],"development":[176],"reviewed.":[178],"issue":[180],"vs.":[184],"affordability":[185],"then":[187],"addressed":[188],"suggestions":[190],"that":[191],"facilitate":[192],"access":[194],"sustainability":[197],"presented.":[199]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":6},{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":10},{"year":2022,"cited_by_count":7},{"year":2021,"cited_by_count":5},{"year":2020,"cited_by_count":15},{"year":2019,"cited_by_count":7},{"year":2018,"cited_by_count":1}],"updated_date":"2026-11-07T11:25:07.637180","created_date":"2018-05-17T00:00:00"}